Business Wire

Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline

Del

Kite, a Gilead Company (Nasdaq: GILD), today announced it has leased a new facility in the Netherlands to engineer cell therapies in Europe. The 117,000 square-foot site in Hoofddorp (SEGRO Park Amsterdam Airport) will enable Kite to efficiently manufacture and deliver its cell therapies to people living with cancer in Europe and will provide more than 300 new jobs when fully operational in 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180515005353/en/

The facility will engineer and produce innovative cell therapies, including axicabtagene ciloleucel, a Chimeric Antigen Receptor T cell (CAR T) therapy that is currently under review by the European Medicines Agency and which is approved in the United States as Yescarta®.

“We are pleased to be leading a new frontier of cancer innovation that is bringing hope for people living with cancer,” commented John F. Milligan, PhD, Gilead’s President and Chief Executive Officer. “This new European manufacturing facility will enable personalized cell therapies to be manufactured in closer geographic proximity to the patients who will receive them, potentially shortening the turnaround time for people who urgently need care.”

In addition to the Netherlands facility, Kite has recently purchased a new building in Santa Monica from Astellas Pharma Inc. that will be used for cell therapy research, development and the expansion of clinical manufacturing capabilities, and has leased a 26,000 square-foot facility in Gaithersburg, Maryland. The Maryland site will support the work of a new Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to develop adoptive cell therapies targeting patient-specific tumor neoantigens. Neoantigens are mutations found on the surface of cancer cells that are unique to each person and tumor, offering the potential for more targeted antitumor activity.

“We are proud to be at the forefront of advancing cell therapy, which we believe has the potential to transform cancer treatment,” said Alessandro Riva, MD, Gilead’s Executive Vice President, Oncology Therapeutics & Head, Cell Therapy. “The addition of these three new facilities and the expanded CRADA with our research collaborators at the NCI will help us bring cell therapies to more people with cancer around the world.”

About Kite

Kite, a Gilead Company, is a biopharmaceutical company based in Santa Monica, California. Kite is engaged in the development of innovative cancer immunotherapies. The company is focused on chimeric antigen receptor and T cell receptor engineered cell therapies. For more information on Kite, please visit www.kitepharma.com.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

Forward-Looking Statement

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that Kite may not realize the potential benefits of the new manufacturing facilities and the expanded collaboration with the National Cancer Institute and the risk that the new facilities may not be fully operational in the currently anticipated timelines. Further, the European Commission may not approve axicabtagene ciloleucel in the currently anticipated timelines or at all, and any marketing approval, if granted, may have significant limitations on its use. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include risks and uncertainties detailed from time to time in the companies’ periodic reports filed with the Securities and Exchange Commission, including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K. All forward-looking statements are based on information currently available to Gilead and Kite, and Gilead and Kite assume no obligation and disclaim any intent to update any such forward-looking statements.

US Prescribing Information for Yescarta, including BOXED WARNING and Medication Guide, is available at www.kitepharma.com and www.gilead.com .

For more information on Kite, please visit the company’s website at  www.kitepharma.com . Learn more about Gilead at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-300.

Contact information

Gilead Sciences
Investors
Sung Lee, +1 650-524-7792
or
Media (Europe)
Sarah Swift, +44 (208) 587-2618
or
Media (U.S.)
Nathan Kaiser, +1 650-522-1853

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

myPOS Presented with Best POS Innovation Award by the Merchant Payment Ecosystem21.2.2019 14:57:00Pressemelding

myPOS, one of the fastest growing European payment providers was handed the Best POS Innovation/POS Software Payment Applications award for 2019 by the Merchant Payment Ecosystem (MPE) at a Gala Dinner ceremony in Berlin last night. Being known for offering instant settlement and no-monthly-fees model to SMEs across Europe, myPOS provides a range of innovative features on its payment devices, some of which include Tipping, Payment Request, Top-up and GiftCards. In addition, myPOS merchants are entitled to a whole range of subscription-free, value-added services such as Virtual MO/TO, PayLinks and PayButtons, Checkout module with the most popular shopping carts and more. myPOS clients are also given the opportunity to manage their funds with a free online account and a unique banking platform. The company got nominated in two categories: Best POS Innovation and Best Acquirer of the year, but ultimately won the Best POS Innovation award. "We accept this award with gratitude and appreciat

New Release Crea Records: "ABBA We Love You Forever"21.2.2019 14:44:00Pressemelding

Not many people on this earth can say that they have never heard of ABBA. In addition to the wonderful voices of Agnetha Fältskog and Anni-Fried Lyngstad, the musicians, Björn Ulvaeus and Benny Andersson have written the most wonderful songs, not only composed with charm and elegance, but also so breathtakingly beautiful and unforgettable that they will always resonate. For the Danish singer, BILLBOARD Hot 100 artist, composer and lyricist, Lecia Jonsson, ABBA has been much more than an inspiration. Lecia shared the same melodic universe as ABBA, making her mark with many records as part of duo LECIA & LUCIENNE. Later, as part of another duo, LABAN, Lecia entered BILLBOARD HOT 100 in the United States, had releases in 48 countries worldwide, and sold more than 1.5 million albums. Lecia’s identity is formed by her pure voice and her great sense for writing unique songs filled with a great melodic substance. If anyone should write a song to honour ABBA’s music, Lecia is definitely the pe

Ultivue Expands Global Presence with Opening of European Subsidiary, Ultivue EMEA Srl21.2.2019 14:30:00Pressemelding

Ultivue, a developer of tissue biomarker identification and quantification assays for pathology and translational research labs, today announced that it has expanded its commercial footprint with a wholly-owned European subsidiary and appointed Luigi Pirovano as General Manager. Mr. Pirovano is an international executive with significant experience managing European Diagnostics and Life Science operations and will be responsible for managing the new subsidiary, Ultivue EMEA Srl, located in Milan, Italy. “The establishment of a European subsidiary provides an excellent structure to support Ultivue’s expanded commercial activities across Europe and engage deeply and efficiently with the biomedical community,” said Philippe Mourere, Ultivue’s Senior Vice President of Commercial Operations. “Ultivue will capitalize on Luigi’s demonstrated success leading both Life Science and Diagnostics activities to continue driving strong execution of its business plan.” Luigi Pirovano has more than 30

Seoul Semiconductor Made Global Distributor Stop Selling Everlight Product in Japan21.2.2019 14:00:00Pressemelding

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890) (“Seoul”), a leading global innovator of LED products and technology, announced that it has concluded a patent infringement lawsuit seeking an injunction on the sales of certain LED product sold by Mouser Electronics (“Mouser”). The accused LED product was manufactured by Everlight Electronics Co., Ltd. (“Everlight”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190221005040/en/ Seoul Semiconductor's Headquarters in Korea (Photo: Business Wire) In February 2018, Seoul filed a patent infringement lawsuit with the Tokyo District Court, accusing the LED product manufactured by Everlight and sold by Mouser of infringing an LED patent of Seoul’s affiliate. Mouser agreed not to export the accused Everlight LED product in Japan, and Seoul therefore agreed to withdraw the lawsuit. The patented technology involved in this litigation serves to efficiently extract light emitted from the i

NTT DATA Launches Advanced 3D Digital Map Package for 5G Network Planning21.2.2019 14:00:00Pressemelding

NTT DATA (TOKYO:9613), a leading IT services provider, announced today its launch of “AW3D Telecom for 5G,” an advanced 3D digital map package that leverages high-quality satellite imagery for the planning of fifth-generation (5G) wireless networks, effective immediately. AW3D for 5G is expected to be used by telecom carriers, network vendors and IoT companies engaged in businesses involving 5G networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190221005320/en/ Images of AW3D Telecom for 5G (Graphic: Business Wire) Commercial 5G services via fixed wireless access networks launched in the USA in 2018 and will begin operating in Japan, South Korea, the UK and Australia in 2019. Accurate 3D models are crucial for designing 5G networks, which use millimeter-spectrum waves that are highly sensitive to interference from natural and manmade objects. Buildings, trees, bridges, flyover roads, etc. need to be expressed precisely

Universal Laser Systems Maximizes Material Compatibility in New ULTRA 9 Platform21.2.2019 13:05:00Pressemelding

With the increasing use of advanced materials in industrial applications from aerospace to medical devices comes a growing need for innovation in material conversion technology. Developments in laser processing aim to overcome the limitations of existing technology and push the boundaries of how materials can be used. To this end, Universal Laser Systems has released a platform with unprecedented material processing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190221005340/en/ ULTRA 9 laser platform (Photo: Business Wire) The new ULTRA 9 Platform is designed to perform laser cutting, laser ablation, and laser surface modification. When configured with patented MultiWave Hybrid™ technology, it can combine the laser energy of up to three wavelengths – 9.3 µm (CO2), 10.6 µm (CO2), and 1.06 µm (fiber) – by independently controlling each spectral component of the beam. The user is able to select the ideal waveleng